NCT02934776

Brief Summary

The purpose of this study is to examine if investigators can improve diagnosis of prostate cancer by using MRI/DTI?

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 11, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 17, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

October 10, 2017

Status Verified

October 1, 2017

Enrollment Period

2.3 years

First QC Date

October 11, 2016

Last Update Submit

October 9, 2017

Conditions

Keywords

DTIprostate cancerMRI

Outcome Measures

Primary Outcomes (1)

  • Compare between number of prostate cancer diagnosed by mpMRI to the ones diagnosed by MRI/DTI

    1 year

Secondary Outcomes (4)

  • Compare the correlation of MRI/DTI parameters with prostate cancer diagnosis to the ones measured by mpMRI (ADC, and diffusion weighted images).

    1 year

  • Compare between MRI/DTI and MRI ability to identify low-grade and high-grade prostate cancer

    1 year

  • Compare between MRI/DTI and MRI in their ability to estimate tumor size.

    1 year

  • Compare between MRI/DTI and MRI in PiRAD grading

    1 year

Study Arms (1)

DTI acquisition

EXPERIMENTAL

Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images

Device: MRI machine

Interventions

The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.

Also known as: Ingenia 3.0T
DTI acquisition

Eligibility Criteria

Age18 Years - 90 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men who are scheduled to undergo MRI of the prostate at the Department of Imaging, in Beilinson Hospital, Rabin Medical Center
  • Age 18-90.
  • Men who are willing and able to sign an informed consent form.

You may not qualify if:

  • \) Men who cannot complete the full acquisition of the MRI and the MRI/DTI image sequences for any reason.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rabin Medical Center

Petah Tikva, 4941492, Israel

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Uro-Oncologist

Study Record Dates

First Submitted

October 11, 2016

First Posted

October 17, 2016

Study Start

August 1, 2016

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

October 10, 2017

Record last verified: 2017-10

Locations